Prophylactic early erythropoietin for neuroprotection in preterm infants: A meta-analysis

Pediatrics

Volumn 139, Issue 5, 2017, Pages

  Fischer, Hendrik S ^a   Reibel, Nora J ^a   Buhrer, Christoph ^a   Dame, Christof ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; BAYLEY SCALES OF INFANT DEVELOPMENT; CEREBRAL PALSY; CLINICAL ASSESSMENT TOOL; CLINICAL OUTCOME; DEVELOPMENTAL DISORDER; DRUG USE; EARLY INTERVENTION; HEARING IMPAIRMENT; HUMAN; INCIDENCE; INFANT; MEDICAL LITERATURE; MENTAL DEVELOPMENTAL INDEX; META ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; OUTCOME ASSESSMENT; PEER REVIEW; PREMATURITY; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; COGNITION DISORDERS; DEVELOPMENTAL DISABILITIES; NEWBORN; PHYSIOLOGY;

COGNITION DISORDERS; DEVELOPMENTAL DISABILITIES; ERYTHROPOIETIN; HUMANS; INFANT; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; NEUROPROTECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 85019025598     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-4317     Document Type: Review

References (64)

1. Patel RM, Kandefer S, Walsh MC, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med. 2015;372(4):331-340
2. Jeschke E, Biermann A, Gunster C, et al.; Routine Data-Based Quality Improvement Panel. Mortality and major morbidity of very-low-birth weight infants in Germany 2008-2012: a report based on administrative data. Front Pediatr. 2016;4:23
3. Serenius F, Ewald U, Farooqi A, et al.; Extremely Preterm Infants in Sweden Study Group. Neurodevelopmental outcomes among extremely preterm infants 6.5 years after active perinatal care in Sweden. JAMA Pediatr. 2016;170(10):954-963
4. Laptook AR, O'Shea TM, Shankaran S, Bhaskar B; NICHD Neonatal Network. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics. 2005;115(3):673-680
5. Robertson NJ, Tan S, Groenendaal F, et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? J Pediatr. 2012;160(4):544-552.e4
6. Ruegger CM, Hagmann CF, Buhrer C, Held L, Bucher HU, Wellmann S; EpoRepair Investigators. Erythropoietin for the repair of cerebral injury in very preterm infants (EpoRepair). Neonatology. 2015;108(3):198-204
7. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26(4):1269-1274
8. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab. 2000;279(6):E1242-E1248
9. Wallach I, Zhang J, Hartmann A, et al. Erythropoietin-receptor gene regulation in neuronal cells. Pediatr Res. 2009;65(6):619-624
10. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97(19):10526-10531
11. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004;85(2):138-144
12. Alnaeeli M, Wang L, Piknova B, Rogers H, Li X, Noguchi CT. Erythropoietin in brain development and beyond.Anat Res Int. 2012;2012:953264
13. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke. 2007;38(10):2795-2803
14. Jantzie LL, Miller RH, Robinson S. Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury. Pediatr Res. 2013;74(6):658-667
15. Gonzalez FF, Larpthaveesarp A, McQuillen P, et al. Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke. 2013;44(3):753-758
16. Ohls RK, Christensen RD, Widness JA, Juul SE. Erythropoiesis stimulating agents demonstrate safety and show promise as neuroprotective agents in neonates. J Pediatr. 2015;167(1):10-12
17. Ohls RK, Ehrenkranz RA, Das A, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114(5):1287-1291
18. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006;118(3). Available at: www. pediatrics. org/cgi/content/full/118/3/e635
19. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol. 2010;67(5):657-666
20. Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014;133(6):1023-1030
21. Ohls RK, Cannon DC, Phillips J, et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics. 2016;137(3):e20153859
22. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol. 1999;19(6 pt 1):403-406
23. Luciano R, Fracchiolla A, Ricci D, et al. Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report. Ital J Pediatr. 2015;41:64
24. Fauchere JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122(2):375-382
25. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383-391
26. Zhang J, Wang Q, Xiang H, Xin Y, Chang M, Lu H. Neuroprotection with erythropoietin in preterm and/or low birth weight infants. J Clin Neurosci. 2014;21(8):1283-1287
27. Wang H, Zhang L, Jin Y. A metaanalysis of the protective effect of recombinant human erythropoietin (rhEPO) for neurodevelopment in preterm infants. Cell Biochem Biophys. 2015;71(2):795-802
28. He JS, Huang ZL, Yang H, Weng KZ, Zhu SB. Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi. 2008;10(5):586-588
29. Wang YH. Effects of erythropoietin on anemia and nervous system of premature infants. J Med Forum. 2005;26(7):49-52
30. Wang YH. Effects of recombinant human erythropoietin on neurobehavioral development in premature infants. Chin J Pract Pediatr. 2006;12(1):59-60
31. Song J, Sun H, Xu F, et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016;80(1):24-34
32. Natalucci G, Latal B, Koller B, et al.; Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA. 2016;315(19):2079-2085
33. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993
34. Bayley N. Bayley Scales of Infant and Toddler Development Screening Test. 3rd ed. San Antonio, TX: Harcourt Assessment; 2006
35. Johnson S, Moore T, Marlow N. Using the Bayley-III to assess neurodevelopmental delay: which cut-off should be used? Pediatr Res. 2014;75(5):670-674
36. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London, UK: The Cochrane Collaboration; 2011. Available at: www. cochrane-handbook. org. Accessed May 15, 2016
37. World Health Organization. International Clinical Trials Registry Platform (ICTRP). World Health Organization website. Available at: www. who. int/ictrp/en/. Accessed December 18, 2016
38. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc. 2006;94(1):41-47
39. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097
40. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700
41. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002
42. Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatrics. 2000;105(5):1066-1072
43. Maier RF, Obladen M, Kattner E, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group. J Pediatr. 1998;132(5):866-870
44. Shannon KM, Mentzer WC, Abels RI, et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Pediatr. 1991;118(6):949-955
45. Shannon KM, Mentzer WC, Abels RI, et al. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. J Pediatr. 1992;120(4 pt 1): 586-592
46. Shannon KM, Keith JF III, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 1995;95(1):1-8
47. Ohls RK, Christensen RD, Kamath-Rayne BD, et al. A randomized, masked, placebocontrolled study of darbepoetin alfa in preterm infants. Pediatrics. 2013;132(1). Available at: www. pediatrics. org/cgi/content/full/132/1/e119
48. Juul SE, Mayock DE, Comstock BA, Heagerty PJ. Neuroprotective potential of erythropoietin in neonates; design of a randomized trial. Matern Health Neonatol Perinatol. 2015;1:27
49. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2014;4:CD004863
50. Xu XJ, Huang HY, Chen HL. Erythropoietin and retinopathy of prematurity: a meta-analysis. Eur J Pediatr. 2014;173(10):1355-1364
51. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against lightinduced retinal degeneration. Nat Med. 2002;8(7):718-724
52. Fang JL, Sorita A, Carey WA, Colby CE, Murad MH, Alahdab F. Interventions to prevent retinopathy of prematurity: a meta-analysis. Pediatrics. 2016;137(4):e20153387
53. McAdams RM, McPherson RJ, Mayock DE, Juul SE. Outcomes of extremely low birth weight infants given early high-dose erythropoietin. J Perinatol. 2013;33(3):226-230
54. Kersbergen KJ, Makropoulos A, Aljabar P, et al. Longitudinal regional brain development and clinical risk factors in extremely preterm infants. J Pediatr. 2016;178:93-100.e6
55. Raets MM, Dudink J, Govaert P. Neonatal disorders of germinal matrix. J Matern Fetal Neonatal Med. 2015;28(suppl 1):2286-2290
56. Leuchter RH, Gui L, Poncet A, et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA. 2014;312(8):817-824
57. Marlow N. Is survival and neurodevelopmental impairment at 2 years of age the gold standard outcome for neonatal studies? Arch Dis Child Fetal Neonatal Ed. 2015;100(1):F82-F84
58. Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colonystimulating factor for neonatal sepsis: childhood outcomes at 5 years. Arch Dis Child Fetal Neonatal Ed. 2015;100(4):F320-F326
59. Rosebraugh MR, Widness JA, Nalbant D, Cress G, Veng-Pedersen P. Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatr Res. 2014;75(2):336-342
60. Rayjada N, Barton L, Chan LS, Plasencia S, Biniwale M, Bui KC. Decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants: a retrospective study. Neonatology. 2012;102(4):287-292
61. Meyer MP. Bronchopulmonary dysplasia and erythropoietin. Concerning the article by N. Rayjada et al.: decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants: a retrospective study [Neonatology 2012;102:287-292]. Neonatology. 2013;103(2):123
62. Doege C, Pritsch M, Fruhwald MC, Bauer J. An association between infantile haemangiomas and erythropoietin treatment in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2012;97(1):F45-F49
63. Lowe JR, Erickson SJ, Schrader R, Duncan AF. Comparison of the Bayley II Mental Development Index and the Bayley III Cognitive Scale: are we measuring the same thing? Acta Paediatr. 2012;101(2):e55-e58
64. Moore T, Johnson S, Haider S, Hennessy E, Marlow N. Relationship between test scores using the second and third editions of the Bayley Scales in extremely preterm children. J Pediatr. 2012;160(4):553-558